NCT00354458View on ClinicalTrials.gov

PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

PHASE3CompletedINTERVENTIONAL

Enrollment

1,102

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Heart Failure, Congestive

Interventions

DRUG

rolofylline

rolofylline 30 mg IV QD; 3 days

DRUG

Comparator: Placebo (unspecified)

rolofylline Pbo 30 mg IV QD; 3 days

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00354458 - PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function | Biotech Hunter | Biotech Hunter